Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction in RSV-associated hospitalizations among infants aged 0–7 months. The largest benefits were seen in the youngest and most vulnerable infants, particularly during peak winter months.